Sugi Predict

Sugi Predict / Compounds / SCHEMBL16021406

SCHEMBL16021406

SCHEMBL16021406

Cc1cc(B2OC(C)(C)C(C)(C)O2)cc(F)c1CO

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 1/20 0.40
▸ LIPG Q9Y5X9 11/20 0.39
▸ LPL P06858 10/20 0.39
▸ F11 P03951 2/20 0.34
▸ FFAR1 O14842 1/20 0.33
▸ ESR2 Q92731 1/20 0.32
▸ PDGFRB P09619 1/20 0.31
▸ KDR P35968 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA9 Q16790 1/20 0.31
▸ EGFR P00533 1/20 0.31
▸ F2 P00734 1/20 0.30
▸ PRSS1 P07477 1/20 0.30
▸ PRSS2 P07478 1/20 0.30
▸ PRSS3 P35030 1/20 0.30
▸ HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16011151 0.92 ROCK1 (0.36) ROCK1LIPGLPLF11FFAR1
SCHEMBL16021403 0.90 LIPG (0.43) ROCK1LIPGLPLF11FFAR1
SCHEMBL14488668 0.83 ROCK1 (0.39) ROCK1LIPGLPLF11FFAR1
SCHEMBL16011263 0.82 ROCK1 (0.44) ROCK1LIPGLPLF11FFAR1
SCHEMBL14488072 0.81 ROCK1 (0.38) ROCK1LIPGLPLF11FFAR1
SCHEMBL19647680 0.80 ROCK1 (0.40) ROCK1LIPGLPLF11FFAR1
SCHEMBL13064191 0.80 ROCK1 (0.40) ROCK1LIPGLPLF11FFAR1
SCHEMBL20563354 0.79 ROCK1 (0.42) ROCK1LIPGLPLPDGFRBKDR
SCHEMBL25430031 0.79 LPL (0.42) ROCK1LIPGLPLF11FFAR1
SCHEMBL780202 0.79 ROCK1 (0.39) ROCK1LIPGLPLF11FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11401272-B2 Heterocyclic compounds as LSD1 inhibitors INCYTE CORPORATION (US) 2022-08-02 — — US disclosed
CN-107660205-B Heterocyclic compounds as LSD1 inhibitors 因赛特公司 2021-08-27 — — CN disclosed
US-20200392143-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS INCYTE CORPORATION 2020-12-17 — — US disclosed
US-20200392143-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS INCYTE CORPORATION 2020-12-17 — — US disclosed
US-10800779-B2 Heterocyclic compounds as LSD1 inhibitors INCYTE CORPORATION (US) 2020-10-13 — — US disclosed
US-10800779-B2 Heterocyclic compounds as LSD1 inhibitors INCYTE CORPORATION (US) 2020-10-13 — — US disclosed
US-10640503-B2 Imidazopyridines and imidazopyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2020-05-05 — — US disclosed
US-10640503-B2 Imidazopyridines and imidazopyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2020-05-05 — — US disclosed
EP-3626720-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS Incyte Corporation (US) 2020-03-25 — — EP disclosed
EP-3626720-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS Incyte Corporation (US) 2020-03-25 — — EP disclosed
US-20160009720-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 — — US disclosed
US-20160009720-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 — — US disclosed
US-20160009720-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 — — US disclosed
WO-2016007736-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2016-01-14 — — WO disclosed
WO-2016007731-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2016-01-14 — — WO disclosed
US-20160009712-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 — — US disclosed
US-20160009712-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 — — US disclosed
WO-2016007731-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2016-01-14 — — WO disclosed
US-9040691-B2 Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-05-26 — — US disclosed
US-20140256718-A1 HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11401272-B2 Heterocyclic compounds as LSD1 inhibitors KDM1B, KDM1A, DOT1L ROCK1 1257/4885LIPG 1842/4885LPL 3226/4885
US-20160009720-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS KDM1B, KDM2A, KDM1A ROCK1 1644/4885LIPG 3687/4885LPL 4054/4885
US-20200392143-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS KDM1B, KDM1A, DOT1L ROCK1 1257/4885LIPG 1842/4885LPL 3226/4885
US-20160009712-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS KDM5A, KDM1A, KDM1B ROCK1 1686/4885LIPG 3962/4885LPL 4146/4885
US-20140256718-A1 HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS ALK, FLT1, ACVR1 ROCK1 35/4885LIPG 172/4885LPL 3561/4885
US-10800779-B2 Heterocyclic compounds as LSD1 inhibitors KDM1B, KDM1A, DOT1L ROCK1 1257/4885LIPG 1842/4885LPL 3226/4885
US-10640503-B2 Imidazopyridines and imidazopyrazines as LSD1 inhibitors KDM5A, KDM1A, KDM1B ROCK1 832/4885LIPG 4054/4885LPL 4359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.